Abiopharma

Eliem Therapeutics Inc (ELYM) Announces Clinical Trial Update Eliem Therapeutics Inc (ELYM) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: trial, milestones
• Diseases/Conditions: a fulsome evaluation of budoprutug, budoprutug PrisMN Phase 2 trial in pMN
• Clinical Stage: Phase 1, clinical trial
• Collaboration: Climb Bio, Inc.
  • targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic B-cell activity in autoimmune diseases. CLYM116 employs a novel pH-dependent bind-and-release ‘sweeper’ mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for rapid, deep, and durable inhibition of APRIL with a favorable safety profile and less frequent dosing. CLYM116 is being advanced for the treatment of IgA nephropathy (IgAN) and may also have broader utility across other B-cell mediated diseases where APRIL plays a critical role. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995
  • expected into 2028